NCT06888973View on ClinicalTrials.gov

Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2026

Conditions
Rheumatoid ArthritisSystemic Lupus Erythematosus (SLE)Systemic SclerosisAnkylosing Spondylitis (AS)Juvenile Idiopathic ArthritisPolymyositis/Dermatomyositis
Interventions
BIOLOGICAL

Mesenchymal Stem Cells

allogeneic bone marrow-derived mesenchymal stem cells therapy

OTHER

Placebo

0.9% Saline as placebo

Trial Locations (2)

Unknown

Armed Forces Bone Marrow Transplant Centre/ National Institute of Blood and Marrow Transplant (AFBMTC/NIBMT), Rawalpindi

Pak Emirates Military Hospital, Rawalpindi

All Listed Sponsors
collaborator

Pak Emirates Military Hospital

OTHER

lead

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

OTHER_GOV